Paige.ai, a Memorial Sloan Kettering spinout, has obtained more than $70m to date and will use the series B to expand its market presence and product line.
Paige.ai, a US-based computational cancer diagnostics tool developer based on Memorial Sloan Kettering Cancer Center research, completed a $45m series B round on Wednesday led by Healthcare Venture Partners.
The round was filled out by Brey Capital, private investor Kenan Turnacioglu and undisclosed funds.
Founded in 2018, Paige develops artificial intelligence (AI)-equipped software tools that help pathologists diagnose biomarkers indicative of cancer by comparing digitised patient scans with its genomic data library.
In addition to its own platform, Paige plans to market the technology via industry partnerships, having recently concluded a deal with electronics and healthcare technology producer Philips.
The fresh capital will help Paige pursue US regulatory clearance, while also supporting expansion in Europe, Brazil and Canada. Paige also expects to expand its product pipeline, continuing to focus on biomarker-driven cancer pathology.
Paige was founded by Thomas Fuchs, who leads Memorial Sloan’s research into…
